News and Announcements
BPS Extends into China with $2m Distribution Agreement
- Published June 08, 2016 9:42AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
6th June 2016, ASX Announcement
Highlights:
BPS to facilitate the sale and distribution of Morlife Australian functional foods in China
BPS to earn a merchant transaction and marketing fee on all goods sold
Leading financial technology platform provider BPS Technology Limited (ASX: BPS, “the Company”) is pleased to announce it has executed a Merchant Agreement to facilitate the selling and distribution of Morlife health products into China’s market on Alibaba’s 1688.com, via its Master Merchant Agreement with SmartTrans Holdings Limited (ASX: SMA).
Morlife, Australia’s leading innovator in functional foods, is the first of BPS’ merchants to sell through Alibaba’s sales channel via the landmark agreement BPS announced on 18 May 2016. The company is planning further arrangements for more BPS merchants to take advantage of this new sales channel, initially in the Health and Superfoods, Property, Travel and Education categories.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
